Last reviewed · How we verify
Chloroquine diphosphate
Chloroquine diphosphate is a Antimalarial agent; 4-aminoquinoline Small molecule drug developed by University of Sao Paulo General Hospital. It is currently FDA-approved for Malaria (treatment and prophylaxis), Rheumatoid arthritis, Systemic lupus erythematosus. Also known as: Chloroquine, chloroquine.
Chloroquine diphosphate is an antimalarial agent that accumulates in parasitic food vacuoles and inhibits heme polymerization, leading to parasite death.
Chloroquine diphosphate is an antimalarial agent that accumulates in parasitic food vacuoles and inhibits heme polymerization, leading to parasite death. Used for Malaria (treatment and prophylaxis), Rheumatoid arthritis, Systemic lupus erythematosus.
At a glance
| Generic name | Chloroquine diphosphate |
|---|---|
| Also known as | Chloroquine, chloroquine |
| Sponsor | University of Sao Paulo General Hospital |
| Drug class | Antimalarial agent; 4-aminoquinoline |
| Target | Heme; Toll-like receptors (secondary immunomodulatory effects) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease; Immunology |
| Phase | FDA-approved |
Mechanism of action
Chloroquine enters the food vacuole of malaria parasites and binds to heme, preventing its detoxification into hemozoin. This causes toxic heme accumulation and parasite death. The drug also has immunomodulatory properties, including inhibition of toll-like receptor signaling and autophagy, which contribute to its anti-inflammatory effects in certain conditions.
Approved indications
- Malaria (treatment and prophylaxis)
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Discoid lupus erythematosus
Common side effects
- Nausea and vomiting
- Abdominal pain
- Headache
- Pruritus
- Retinopathy (with prolonged use)
- Cardiomyopathy (rare, with high doses)
Key clinical trials
- Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer (PHASE1)
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar (PHASE3)
- The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (NA)
- Hydroxychloroquin (HCQ) in chILD of Genetic Defect (NA)
- Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes (EARLY_PHASE1)
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chloroquine diphosphate CI brief — competitive landscape report
- Chloroquine diphosphate updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI
Frequently asked questions about Chloroquine diphosphate
What is Chloroquine diphosphate?
How does Chloroquine diphosphate work?
What is Chloroquine diphosphate used for?
Who makes Chloroquine diphosphate?
Is Chloroquine diphosphate also known as anything else?
What drug class is Chloroquine diphosphate in?
What development phase is Chloroquine diphosphate in?
What are the side effects of Chloroquine diphosphate?
What does Chloroquine diphosphate target?
Related
- Drug class: All Antimalarial agent; 4-aminoquinoline drugs
- Target: All drugs targeting Heme; Toll-like receptors (secondary immunomodulatory effects)
- Manufacturer: University of Sao Paulo General Hospital — full pipeline
- Therapeutic area: All drugs in Infectious Disease; Immunology
- Indication: Drugs for Malaria (treatment and prophylaxis)
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Systemic lupus erythematosus
- Also known as: Chloroquine, chloroquine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing